GOLDSTEIN: Canada rolls the dice by delaying second vaccine shot winnipegsun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from winnipegsun.com Daily Mail and Mail on Sunday newspapers.
Vee Tech, Sona Group join Canada s UHN on wearable research
By IANS |
Published on
Fri, Mar 5 2021 12:18 IST |
0 Views
Vee Tech, Sona Group join CanadaÂs UHN on wearable research. Image Source: IANS News
Toronto, March 5 : Technology services firm Vee Technologies and Sona Group of educational institutions have signed an agreement with Toronto-based University Health Network (UHN) to develop smart fabric-based wearables.
The aim is to improve the lives of people living with health-related challenges.
As part of the agreement, Bengaluru and New York co-headquartered Vee Technologies will make significant cash contributions to the current and future research projects to be undertaken by the collaborating institutions, universities and hospitals in Canada.
A majority of patients with advanced
EGFR/HER2-mutant non-small cell lung cancer (NSCLC) benefited from treatment with the tyrosine kinase inhibitor (TKI) poziotinib, according to a preliminary clinical trial.
An efficacy cohort of 79 patients who received investigational poziotinib 16 mg as initial therapy had an objective response rate (ORR) of 28% and disease control rate (DCR) of 86%. Overall, 72 of 79 (91%) patients had tumor reduction averaging 25.5%. Initial data from an ongoing dosing evaluation involving previously treated and untreated patients showed objective responses in seven of 30 patients and stable disease in 11 treated with 16 mg, resulting in a DCR of 60%.
Tolerability remains a challenge, as a majority of patients in the dosing study required treatment interruptions and dose reductions, and about a third of patients treated with 16 mg had grade ≥3 adverse events, reported Adrian Sacher, MD, of Princess Margaret Cancer Center in Toronto, during the European S
Charlotte’s next act: Life after lymphoma
In 2018, diffuse large B-cell lymphoma (DLBCL) nearly robbed Charlotte of her life. Now, thanks to cell therapies, she’s savouring every moment. By D.F. McCourt
Created by
At age 64, Charlotte Grad was showing no sign of slowing down. She was an avid traveller, a loving grandmother, a theatre regular and a fitness enthusiast. If she wasn’t at the gym, she was hiking or cycling one of the many trails near her Markham, Ont., home. Charlotte and her partner of 23 years, Colin, were keen to get the most out of every moment.
E-Mail
IMAGE: Darren Bidulka rests after his modified blood stem cells were transplanted into him at the Foothills Medical Centre in Calgary in 2017, allowing him to stop his enzyme therapy. (From. view more
Credit: Courtesy of Darren Bidulka
(Thursday, Feb. 25, 2021, Toronto) Results of a world-first Canadian pilot study on patients treated with gene therapy for Fabry disease show that the treatment is working and safe.
The Canadian research team was the first to use gene therapy in 2017 to treat patients with Fabry disease, a rare, chronic illness that can damage major organs and shorten lives. They report their findings today in the journal